Dr. Yong-Sung Kim has been a professor in the Dept. of Molecular Science and Technology at Ajou University (Suwon, Korea) since 2004. After obtaining a Ph.D. degree in Pharmaceutical Sciences in 2002 from the University of Colorado, Denver, he joined the lab of Prof. K. Dane Wittrup at MIT as a post-doc for protein and antibody engineering using yeast surface display. During his Sabbatical, he spent one year (2010-2011) at Genentech Inc. (SF, USA), where he worked with scientists at Depts. of molecular oncology and antibody engineering. Dr. Kim’s research focuses on the development of next-generation antibody platform technology for potent anti-cancer therapeutics, including heterodimeric Fc-based bispecific antibody, solid tumor-penetrating antibody platform, and cellular cytosol-penetrating antibody platform technology. Dr. Kim has published more than 110 articles in peer-reviewed scientific journals, including Nature Communications, Science Advances, Cancer Immunology Research, Molecular Cancer, PNAS, Cancer Research, Molecular Cancer Therapeutics, Journal of Controlled Release, Oncogene, Nucleic Acid Research, etc. He also filed and obtained numerous domestic and international patents. Based on the cellular cytosol-penetrating antibody technology, Dr. Kim co-founded Orum Therapeutics Inc. in 2016 for the commercialization of the platform technology. Dr. Kim also cofounded Pinetree Therapeutics Inc. in Boston, USA, to commercialize NRP1-targeting bispecific antibodies. In addition, Dr. Kim has transferred 5 antibody-related technologies to companies in Korea and USA. His website is http://antibody.ajou.ac.kr/.